Risk of Head and Neck Cancer in Patients With Prior Hematologic Malignant Tumors | Head and Neck Cancer | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Risk of Head and Neck Cancer in Patients With Prior Hematologic Malignant Tumors

Educational Objective
To determine a possible association between previously diagnosed hematologic malignant disease and the development of head and neck cancer.
1 Credit CME
Key Points

Question  Is there an association between increased risk and worse survival outcomes in patients with head and neck cancer and a history of hematologic malignant tumors?

Findings  In a study of 30 939 656 patients, prior hematologic malignant tumors were associated with the development of head and neck cancer at multiple subsites; 2-year and 5-year overall survival rates were also worse among patients with a history of hematologic malignant tumors for several head and neck cancer subsites.

Meaning  The findings suggest that patients with hematologic malignant tumors are at higher risk of developing head and neck cancers and that overall survival may be worse for patients with head and neck cancer and a history of hematologic malignant tumors.

Abstract

Importance  More than 1.3 million people in the United States have a hematologic malignant tumor currently or in remission. Previous studies have demonstrated an increased risk of secondary neoplasms in patients with hematologic malignant tumors, but research specifically on the risk of head and neck solid tumors in patients with prior hematologic malignant tumors is limited.

Objectives  To examine a possible association between prior hematologic malignant tumors and risk of head and neck cancer and to assess the overall survival (OS) among these patients.

Design, Setting, and Participants  This retrospective analysis used the Veterans Affairs (VA) Corporate Data Warehouse (CDW) to identify patients with diagnoses of hematologic malignant tumors and head and neck cancers. All patients in the VA CDW with a birthdate between January 1, 1910, and December 31, 1969, were included, for a cohort of 30 939 656 veterans. Data analysis was performed from August 15, 2018, to January 31, 2019.

Exposures  Outpatient problem lists were queried for diagnoses of hematologic malignant tumor and associated malignant tumors using International Classification of Diseases, Ninth Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes to categorize patients by history of hematologic malignant tumors.

Main Outcomes and Measures  Presence of head and neck cancer was determined from ICD-9 and ICD-10 codes of outpatient problem lists, and cancers were grouped by subsite. The OS was determined from date of death or last outpatient visit date.

Results  Of 30 939 656 patients (27 636 683 [89.3%] male; 13 971 259 [45.2%] white), 207 322 patients had a hematologic malignant tumor, of whom 1353 were later diagnosed with head and neck cancer. A history of hematologic malignant tumors was significantly associated with overall aerodigestive tract cancer, with a relative risk (RR) of 1.6 (95% CI, 1.5-1.7), as well as oral cavity (RR, 1.7; 95% CI, 1.5-1.9), oropharynx (RR, 1.7; 95% CI, 1.5-1.9), larynx (RR, 1.3; 95% CI, 1.2-1.5), nasopharynx (RR, 2.8; 95% CI, 2.1-3.9), sinonasal (RR, 3.0; 95% CI, 2.2-4.1), salivary gland (RR, 2.8; 95% CI, 2.4-3.3), and thyroid (RR, 2.1; 95% CI, 1.9-2.4) tumors on subsite analysis. A prior hematologic malignant tumor was also negatively associated with 2-year and 5-year OS for multiple subsites.

Conclusions and Relevance  A prior diagnosis of hematologic or associated malignant tumors was associated with an increased risk of solid head and neck cancers in a range of subsites. In addition, for several head and neck cancer subsites, patients with prior hematologic malignant tumors had worse 2-year and 5-year OS. These results indicate that a prior hematologic malignant tumor may be an adverse risk factor in the development and progression of head and neck cancer.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: April 2, 2019.

Corresponding Author: Daniel Clayburgh, MD, PhD, Department of Otolaryngology–Head and Neck Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code PV01, Portland, OR 97239 (clayburg@ohsu.edu).

Published Online: May 2, 2019. doi:10.1001/jamaoto.2019.1012

Author Contributions: Drs Mowery and Clayburgh had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Mowery, Clayburgh.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Mowery, Clayburgh.

Administrative, technical, or material support: Conlin.

Supervision: Conlin, Clayburgh.

Conflict of Interest Disclosures: Dr Clayburgh reported receiving grants from Abbvie Inc outside the submitted work. No other disclosures were reported.

Meeting Presentation: This article was presented in part at the Annual Meeting of the American Head and Neck Society; May 2, 2019; Austin, Texas.

References
1.
American Cancer Society.  Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society; 2019.
2.
Howlader  NNA, Krapcho  M, Miller  D, Cronin  KA, eds.  SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute; 2017.
3.
Budrukkar  A, Muttagi  S, Shahid  T,  et al.  Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.  Br J Oral Maxillofac Surg. 2012;50(6):504-507. doi:10.1016/j.bjoms.2011.08.012PubMedGoogle ScholarCrossref
4.
Eichenauer  DA, Becker  I, Monsef  I,  et al.  Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.  Haematologica. 2017;102(10):1748-1757. doi:10.3324/haematol.2017.167478PubMedGoogle ScholarCrossref
5.
Giri  S, Bhatt  VR, Verma  V,  et al.  Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study.  Clin Lymphoma Myeloma Leuk. 2017;17(9):569-574. doi:10.1016/j.clml.2017.06.028PubMedGoogle ScholarCrossref
6.
Hisada  M, Chen  BE, Jaffe  ES, Travis  LB.  Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.  J Natl Cancer Inst. 2007;99(3):215-222. doi:10.1093/jnci/djk030PubMedGoogle ScholarCrossref
7.
Mudie  NY, Swerdlow  AJ, Higgins  CD,  et al.  Risk of second malignancy after non-Hodgkin’s lymphoma: a British cohort study.  J Clin Oncol. 2006;24(10):1568-1574. doi:10.1200/JCO.2005.04.2200PubMedGoogle ScholarCrossref
8.
Razavi  P, Rand  KA, Cozen  W, Chanan-Khan  A, Usmani  S, Ailawadhi  S.  Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics.  Blood Cancer J. 2013;3(6):e121. doi:10.1038/bcj.2013.19PubMedGoogle Scholar
9.
Schaapveld  M, Aleman  BM, van Eggermond  AM,  et al.  Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma.  N Engl J Med. 2015;373(26):2499-2511. doi:10.1056/NEJMoa1505949PubMedGoogle ScholarCrossref
10.
Hisada  M, Biggar  RJ, Greene  MH, Fraumeni  JF  Jr, Travis  LB.  Solid tumors after chronic lymphocytic leukemia.  Blood. 2001;98(6):1979-1981. doi:10.1182/blood.V98.6.1979PubMedGoogle ScholarCrossref
11.
Mellemgaard  A, Geisler  CH, Storm  HH.  Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia.  Eur J Haematol. 1994;53(4):218-222. doi:10.1111/j.1600-0609.1994.tb00192.xPubMedGoogle ScholarCrossref
12.
Morton  LM, Curtis  RE, Linet  MS,  et al.  Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.  J Clin Oncol. 2010;28(33):4935-4944. doi:10.1200/JCO.2010.29.1112PubMedGoogle ScholarCrossref
13.
Schöllkopf  C, Rosendahl  D, Rostgaard  K, Pipper  C, Hjalgrim  H.  Risk of second cancer after chronic lymphocytic leukemia.  Int J Cancer. 2007;121(1):151-156. doi:10.1002/ijc.22672PubMedGoogle ScholarCrossref
14.
Travis  LB, Curtis  RE, Hankey  BF, Fraumeni  JF  Jr.  Second cancers in patients with chronic lymphocytic leukemia.  J Natl Cancer Inst. 1992;84(18):1422-1427. doi:10.1093/jnci/84.18.1422PubMedGoogle ScholarCrossref
15.
Tsimberidou  AM, Wen  S, McLaughlin  P,  et al.  Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.  J Clin Oncol. 2009;27(6):904-910. doi:10.1200/JCO.2008.17.5398PubMedGoogle ScholarCrossref
16.
Adhikari  J, Sharma  P, Bhatt  VR.  Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.  Future Oncol. 2015;11(23):3175-3185. doi:10.2217/fon.15.252PubMedGoogle ScholarCrossref
17.
Chen  MH, Chang  PM, Li  WY,  et al.  High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.  Bone Marrow Transplant. 2011;46(4):567-572. doi:10.1038/bmt.2010.163PubMedGoogle ScholarCrossref
18.
Cohen  A, Rovelli  A, Merlo  DF,  et al.  Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.  J Clin Oncol. 2007;25(17):2449-2454. doi:10.1200/JCO.2006.08.9276PubMedGoogle ScholarCrossref
19.
Curtis  RE, Rowlings  PA, Deeg  HJ,  et al.  Solid cancers after bone marrow transplantation.  N Engl J Med. 1997;336(13):897-904. doi:10.1056/NEJM199703273361301PubMedGoogle ScholarCrossref
20.
Danylesko  I, Shimoni  A.  Second malignancies after hematopoietic stem cell transplantation.  Curr Treat Options Oncol. 2018;19(2):9. doi:10.1007/s11864-018-0528-yPubMedGoogle ScholarCrossref
21.
Royle  JA, Baade  PD, Joske  D, Girschik  J, Fritschi  L.  Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.  Br J Cancer. 2011;105(7):1076-1081. doi:10.1038/bjc.2011.313PubMedGoogle ScholarCrossref
22.
Wiernik  PH.  Second neoplasms in patients with chronic lymphocytic leukemia.  Curr Treat Options Oncol. 2004;5(3):215-223. doi:10.1007/s11864-004-0013-7PubMedGoogle ScholarCrossref
23.
Tward  JD, Wendland  MM, Shrieve  DC, Szabo  A, Gaffney  DK.  The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.  Cancer. 2006;107(1):108-115. doi:10.1002/cncr.21971PubMedGoogle ScholarCrossref
24.
Chowdhry  AK, McHugh  C, Fung  C, Dhakal  S, Constine  LS, Milano  MT.  Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma.  Cancer. 2015;121(9):1436-1445. doi:10.1002/cncr.29231PubMedGoogle ScholarCrossref
25.
Chung  JC, Tsang  RK, To  VS,  et al.  Secondary head and neck cancer in patients with history of hematological malignancy.  Head Neck. 2013;35(5):729-732. doi:10.1002/hed.23026PubMedGoogle ScholarCrossref
26.
Fihn  SD, Francis  J, Clancy  C,  et al.  Insights from advanced analytics at the Veterans Health Administration.  Health Aff (Millwood). 2014;33(7):1203-1211. doi:10.1377/hlthaff.2014.0054PubMedGoogle ScholarCrossref
27.
Centers for Disease Control and Prevention. Alcohol Related Disease Impact (ARDI) Application. 2013. https://nccd.cdc.gov/DPH_ARDI/default/default.aspx. Accessed November 28, 2018.
28.
Maynard  C.  Ascertaining Veterans’ Vital Status: VA Data Sources for Mortality Ascertainment and Cause of Death. Database & Methods Cyberseminar Series. Hines, IL: VA Information Resource Center; 2017.
29.
Maule  M, Scélo  G, Pastore  G,  et al.  Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study.  J Natl Cancer Inst. 2007;99(10):790-800. doi:10.1093/jnci/djk180PubMedGoogle ScholarCrossref
30.
Rizzo  JD, Curtis  RE, Socié  G,  et al.  Solid cancers after allogeneic hematopoietic cell transplantation.  Blood. 2009;113(5):1175-1183. doi:10.1182/blood-2008-05-158782PubMedGoogle ScholarCrossref
31.
Roddie  C, Peggs  KS.  Immunotherapy for transplantation-associated viral infections.  J Clin Invest. 2017;127(7):2513-2522. doi:10.1172/JCI90599PubMedGoogle ScholarCrossref
32.
D’Souza  G, Kreimer  AR, Viscidi  R,  et al.  Case-control study of human papillomavirus and oropharyngeal cancer.  N Engl J Med. 2007;356(19):1944-1956. doi:10.1056/NEJMoa065497PubMedGoogle ScholarCrossref
33.
Dasanu  CA, Alexandrescu  DT.  Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.  MedGenMed. 2007;9(4):35.PubMedGoogle Scholar
34.
Castillo  JJ, Gertz  MA.  Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.  Leuk Lymphoma. 2017;58(4):773-780. doi:10.1080/10428194.2016.1217527PubMedGoogle ScholarCrossref
35.
Boukheris  H, Ron  E, Dores  GM, Stovall  M, Smith  SA, Curtis  RE.  Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis.  Cancer. 2008;113(11):3153-3159. doi:10.1002/cncr.23918PubMedGoogle ScholarCrossref
36.
Ronckers  CM, Sigurdson  AJ, Stovall  M,  et al.  Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers.  Radiat Res. 2006;166(4):618-628. doi:10.1667/RR3605.1PubMedGoogle ScholarCrossref
37.
Flores-Obando  RE, Gollin  SM, Ragin  CC.  Polymorphisms in DNA damage response genes and head and neck cancer risk.  Biomarkers. 2010;15(5):379-399.PubMedGoogle ScholarCrossref
38.
Seedhouse  C, Bainton  R, Lewis  M, Harding  A, Russell  N, Das-Gupta  E.  The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.  Blood. 2002;100(10):3761-3766. doi:10.1182/blood-2002-04-1152PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close